Acadia Pharmaceuticals: Multiple Growth Catalysts Ahead [Seeking Alpha]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Seeking Alpha
SummaryNuplazid continues to be a game changer in the Parkinson's Disease Psychosis indication.Multiple clinical and regulatory milestones are expected for pimavanserin in the coming years.Investors should be aware of risks such as business concentration risks and R&D failure risks.ACADIA Pharmaceuticals (Acadia) (Acadia's stable financial condition stems from the commercial success of its only marketed product, Nuplazid. This drug has transformed the standard of care in Parkinson’s disease psychosis and has consistently reported solid progress in terms of revenue trajectory, market share, new patient share, and expanding prescriber base in 2019. The company now awaits major clinical and regulatory milestones for Nuplazid in 2020. The stock thus seems all primed up for upward movement in 2020.Company overviewFounded in 1993 and headquartered in San Diego, California, Acadia Pharmaceuticals is a biopharmaceutical company focused on pioneering novel CNS (central nervous system) therapie
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024Business Wire
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health CanadaBusiness Wire
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
ACAD
Earnings
- 2/27/24 - Miss
ACAD
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/15/24 - Form 3
- ACAD's page on the SEC website